Jazz Pharmaceuticals (JAZZ) Net Cash Flow (2010 - 2026)

Jazz Pharmaceuticals has reported Net Cash Flow for 17 years, with the latest figure at $452.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 181.93% year-over-year to $452.8 million; the trailing twelve-month figure through Mar 2026 stood at -$22.0 million (down 105.28% YoY), and the FY2025 full-year result was -$1.0 billion, down 213.13% from the prior year.
• Net Cash Flow for Q1 2026 stood at $452.8 million, up from $65.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $859.3 million in Q3 2024, with the low at -$676.6 million in Q2 2025.
• Average Net Cash Flow over 5 years is $73.7 million, with a median of $114.4 million recorded in 2023.
• Year-over-year, Net Cash Flow surged 1479.44% in 2024 and plunged 802.71% in 2025.
• Tracing JAZZ's Net Cash Flow over 5 years: stood at $37.2 million in 2022, then jumped by 353.98% to $168.8 million in 2023, then increased by 16.7% to $197.0 million in 2024, then sank by 66.6% to $65.8 million in 2025, then surged by 588.19% to $452.8 million in 2026.
• The last three Net Cash Flow figures came in at $452.8 million (Q1 2026), $65.8 million (Q4 2025), and $136.0 million (Q3 2025), per Business Quant data.

Peer Comparison